Cargando…
MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma
Melanoma-associated antigen 3 (MAGE-A3) expression is generally restricted to the placenta and germline cells of the testis, but it may also be expressed in sarcoma and other cancers and is associated with poor prognosis. Immunotherapy approaches targeting MAGE-A3 in other cancers have shown mixed r...
Autores principales: | Conley, Anthony P., Wang, Wei-Lien, Livingston, John A., Ravi, Vinod, Tsai, Jen-Wei, Ali, Ali, Ingram, Davis R., Lowery, Caitlin D., Roland, Christina L., Somaiah, Neeta, Hwu, Patrick, Yee, Cassian, Subbiah, Vivek, Futreal, Andrew, Lazar, Alexander J., Patel, Shreyaskumar, Roszik, Jason |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562561/ https://www.ncbi.nlm.nih.gov/pubmed/31096717 http://dx.doi.org/10.3390/cancers11050677 |
Ejemplares similares
-
The immune landscape of undifferentiated pleomorphic sarcoma
por: Lazcano, Rossana, et al.
Publicado: (2022) -
Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes
por: Roszik, Jason, et al.
Publicado: (2017) -
Prognostic value of CD34 expression status in patients with myxofibrosarcomas and undifferentiated pleomorphic sarcomas
por: Sugiura, Yoshiya, et al.
Publicado: (2021) -
Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma
por: Keung, Emily Z., et al.
Publicado: (2018) -
Systematic screening identifies a 2‐gene signature as a high‐potential prognostic marker of undifferentiated pleomorphic sarcoma/myxofibrosarcoma
por: Hu, Qinsheng, et al.
Publicado: (2019)